| Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. | breast, |
| Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. | colorectal, |
| ErbB2/ErbB3 dimer functions as an oncogenic unit to drive breast tumor cell proliferation. | breast, |
| HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. | endometrial, |
| The clinical significance between activation of nuclear factor kappa B transcription factor and overexpression of HER-2/neu oncoprotein in Taiwanese patients with breast cancer. | breast, |
| Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. | sarcoma, |
| Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. | nasopharyngeal,laryngeal, |
| DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma. | breast, |
| The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. | pancreatic, |
| An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer. | bladder, |
| Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status. | breast, |
| Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. | breast, |
| The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. | breast, |
| Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR. | neoplasm, |
| Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology. | breast, |
| [C-erbB-2 oncogene amplification in breast cancer in correlation to steroid and epidermal growth factor receptor]. | breast, |
| Detection of the HER-2/neu proto-oncogene protein p185erbB2 by a novel monoclonal antibody (MAB-145ww) in breast cancer membranes from oestrogen and progesterone receptor assays. | breast, |
| C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. | breast, |
| Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma. | breast, |
| c-erbB-2 oncogene product expression and prognosis in gastric carcinoma. | gastric, |